Your browser doesn't support javascript.
loading
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Stern, Howard M; Gardner, Humphrey; Burzykowski, Tomasz; Elatre, Wafaa; O'Brien, Carol; Lackner, Mark R; Pestano, Gary A; Santiago, Angela; Villalobos, Ivonne; Eiermann, Wolfgang; Pienkowski, Tadeusz; Martin, Miguel; Robert, Nicholas; Crown, John; Nuciforo, Paolo; Bee, Valerie; Mackey, John; Slamon, Dennis J; Press, Michael F.
Affiliation
  • Stern HM; Genentech Research and Early Development, South San Francisco, California.
  • Gardner H; AstraZeneca, Waltham, Massachusetts.
  • Burzykowski T; International Drug Development Institute, Louvain-la-Neuve, Belgium.
  • Elatre W; USC/Norris Comprehensive Cancer Center, Los Angeles, California.
  • O'Brien C; Genentech Research and Early Development, South San Francisco, California.
  • Lackner MR; Genentech Research and Early Development, South San Francisco, California.
  • Pestano GA; Ventana Medical Systems, Inc., Tucson, Arizona.
  • Santiago A; USC/Norris Comprehensive Cancer Center, Los Angeles, California.
  • Villalobos I; USC/Norris Comprehensive Cancer Center, Los Angeles, California.
  • Eiermann W; Frauenklinik vom Roten Kreuz, Munich, Germany.
  • Pienkowski T; Maria Sklodowska-Curie (MSC) Centre, Warsaw, Poland.
  • Martin M; Hospital Universitario San Carlos, Madrid, Spain.
  • Robert N; Virginia Cancer Specialists/U.S. Oncology Research Network, Fairfax, Virginia.
  • Crown J; Irish Cooperative Oncology Research Group, St. Vincent's University Hospital, Dublin, Ireland.
  • Nuciforo P; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Bee V; Cancer International Research Group/Translational Research in Oncology, Paris, France.
  • Mackey J; Department of Oncology, University of Alberta, Edmonton, Canada.
  • Slamon DJ; Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, California. press@usc.edu DSlamon@mednet.ucla.edu.
  • Press MF; USC/Norris Comprehensive Cancer Center, Los Angeles, California. press@usc.edu DSlamon@mednet.ucla.edu.
Clin Cancer Res ; 21(9): 2065-74, 2015 May 01.
Article in En | MEDLINE | ID: mdl-25649019
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Drug Resistance, Neoplasm / PTEN Phosphohydrolase Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Drug Resistance, Neoplasm / PTEN Phosphohydrolase Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Document type: Article Country of publication: United States